ELVN
Enliven TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Primary-source guidance still supports a live de-risking path in 2026: additional ENABLE data, FDA alignment, and planned ENABLE-2 initiation, while cash of about $462.6 million was said to fund operations into 1H29 [#PR-2026-03-03] [#10-K-2026-03-03].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -9.3.
What can break
Despite runway into 1H29, the company remains pre-revenue and long-term value still depends on future clinical success and capital access.
Momentum
73
Value
41
Sentiment
58
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $38.00 · Bull $58.00 · Bear $24.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $39.57
Why
Momentum73 · Δ7d -9.3
Value41 · Δ7d +0.1
Sentiment58 · Δ7d +13.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
73
34% active weight
Current posture
7d trendSoftening
Δ7d
-9.3
Δ21d
-23.5
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
58
33% active weight
Current posture
7d trendImproving
Δ7d
+13.4
Δ21d
+13.3
Why this grade
Composite grade B. Momentum 73.2 / Value 41.1 / Sentiment 58.2
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$2.28B
Beta
0.33
Shares Out
59.35M
P/E (TTM) · Derived
-20.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-28.69
Rev YoY
-
EPS YoY
+32.4%
Gross Margin
-
Op Margin
-
Net Debt
-$313.44M
Current Ratio
32.95
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology